4.7 Article

Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 433, Issue 22, Pages -

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2021.167242

Keywords

BRD4; ASXL1; ET domain; ubiquitin; BAP1

Funding

  1. Health Research Council of New Zealand

Ask authors/readers for more resources

Proper regulation of gene expression relies on specific protein-protein interactions between epigenetic regulators. Mutations in genes encoding these regulators, such as ASXL1, can lead to cancer and developmental disorders. This study provides a molecular mechanism for the interaction between ASXL1 and BRD4, showing that ASXL1 truncation enhances BRD4 recruitment to transcriptional complexes.
Proper regulation of gene-expression relies on specific protein-protein interactions between a myriad of epigenetic regulators. As such, mutation of genes encoding epigenetic regulators often drive cancer and developmental disorders. Additional sex combs-like protein 1 (ASXL1) is a key example, where mutations frequently drive haematological cancers and can cause developmental disorders. It has been reported that nonsense mutations in ASXL1 promote an interaction with BRD4, another central epigenetic regulator. Here we provide a molecular mechanism for the BRD4-ASXL1 interaction, demonstrating that a motif near to common truncation breakpoints of ASXL1 contains an epitope that binds the ET domain within BRD4. Binding-studies show that this interaction is analogous to common ET-binding modes of BRD4-interactors, and that all three ASX-like protein orthologs (ASXL1-3) contain a functional ET domain-binding epitope. Crucially, we observe that BRD4-ASXL1 binding is markedly increased in the prevalent ASXL1(Y591X) truncation that maintains the BRD4-binding epitope, relative to full-length ASXL1 or truncated proteins that delete the epitope. Together, these results show that ASXL1 truncation enhances BRD4 recruitment to transcriptional complexes via its ET domain, which could misdirect regulatory activity of either BRD4 or ASXL1 and may inform potential therapeutic interventions. (C) 2021 The Author(s). Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available